Nicholas Frane

Nicholas Frane

Auto-generated profile, based on publicly available information

Nicholas Frane

HealthPartners Orthopedics, Minneapolis, MN, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Journal of Cannabis Research
Verified
Journal Article
Open access
PDF file
NFNicholas Frane
Nicholas Frane
ESErik Stapleton
Erik Stapleton
CICesar Iturriaga
Cesar Iturriaga
MGMaximillian Ganz
Maximillian Ganz
VRVijay Rasquinha
Vijay Rasquinha
RDRobert Duarte
Robert Duarte
Introduction: An estimated 54 million Americans currently suffer from debilitating arthritis. Patients who have exhausted conservative measures can be subject to chronic pain and resort to symptomatic management with anti-inflammatories, acetaminophen, and opioids. Cannabidiol (CBD) is a non-psychoactive cannabinoid that has shown promise in preclinical studies to reduce inflammation and pain associated with arthritis. The purpose of this study was to explore patient perceived effects of cannabidiol on symptoms of arthritis. Methods: A novel anonymous questionnaire was created to evaluate perceived efficacy of cannabidiol for the treatment of arthritis. A self-selected convenience sample (N=428) was recruited through online methods including social media accounts and newsletters (The Arthritis Foundation and Savvy Cooperative) between May 5, 2020, and November 5, 2020. Statistical analysis was performed to determine differences between types of arthritis and improvements in quality-of-life symptoms. Furthermore, a regression analysis was performed to identify variables associated with decreasing or discontinuing other medications. Results: CBD use was associated with improvements in pain (83%), physical function (66%), and sleep quality (66%). Subgroup analysis by diagnosis type (osteoarthritis, rheumatoid, or other autoimmune arthritis) found improvements among groups for physical function (P=0.013), favoring the osteoarthritis group. The overall cohort reported a 44% reduction in pain after CBD use (P<0.001). The osteoarthritis group had a greater percentage reduction (P=0.020) and point reduction (P<0.001) in pain compared to rheumatoid arthritis and other autoimmune arthritis. The majority of respondents reported a reduction or cessation of other medications after CBD use (N=259, 60.5%): reductions in anti-inflammatories (N=129, 31.1%), acetaminophen (N=78, 18.2%), opioids (N=36, 8.6%) and discontinuation of anti-inflammatories (N=76, 17.8%), acetaminophen (N=76, 17.8%), and opioids (N=81, 18.9%). Conclusion: Clinicians and patients should be aware of the various alternative therapeutic options available to treat their symptoms of arthritis, especially in light of the increased accessibility to cannabidiol products. The present study found associations between CBD use and improvements in patient’s arthritis symptoms and reductions in other medications. Future research should focus on exploring the benefits of CBD use in this patient population with clinical trials.

1 January 2020 in JBJS Reviews
Verified
Journal Article
Closed access
NFNicholas Frane
Nicholas Frane
AMAndrew Megas
Andrew Megas
ESErik Stapleton
Erik Stapleton
MGMaximillian Ganz
Maximillian Ganz
ABAdam D. Bitterman
Adam D. Bitterman
» The damaging effects to human tissue caused by radiation exposure have been documented since the first reports regarding use of radiographs in the late nineteenth century. » Orthopaedic surgeons and residents often are undereducated about the risks associated with radiation exposure and the recommended safety precautions to help mitigate these potential risks. » Orthopaedic surgeons need to adopt the ALARA (as low as reasonably achievable) principle: whenever possible, all available precautions should be taken to keep all members of the operating room safe from radiation exposure while emphasizing the best appropriate care for patients. » An emphasis on radiation safety and protection should be universally incorporated into graduate medical education.

1 November 2020 in Journal of Clinical Orthopaedics and Trauma
Verified
Journal Article
Closed access
NFNicholas Frane
Nicholas Frane
CICesar Iturriaga
Cesar Iturriaga
CBChristine Bub
Christine Bub
PRPeter Regala
Peter Regala
GKGus Katsigiorgis
Gus Katsigiorgis
MLMichael Linn
Michael Linn

1 January 2020 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
ESErik J. Stapleton
Erik J. Stapleton
NFNicholas Frane
Nicholas Frane
JLJonathon M. Lentz
Jonathon M. Lentz
DADonna Armellino
Donna Armellino
NKNina Kohn
Nina Kohn
ABAdam D. Bitterman
Adam D. Bitterman
A surgical site infection (SSI) is defined as a superficial or deep infection that occurs within 30 days after a surgical procedure or within 90 days if hardware is retained.1,2 Surgical site infections occur in 2% to 5% of the 30 million patients undergoing inpatient surgery, and these surgical complications can have varying associations with clinical outcomes.3-5 The range of associated morbidity includes additional office visits, return to the operating room for irrigation and debridement, and, in the most severe cases, amputation or death.6 The associated SSI mortality rate is 1.5% to 3%, and 75% of SSI-associated deaths are directly attributable to the acquired SSI.6,7

1 May 2021 in JAAOS: Global Research and Reviews
Verified
Journal Article
Open access
JBJohann Braithwaite
Johann Braithwaite
NFNicholas Frane
Nicholas Frane
MPMatthew J. Partan
Matthew J. Partan
PWPeter B. White
Peter B. White
CICesar Iturriaga
Cesar Iturriaga
ABAdam Bitterman
Adam Bitterman
Introduction: The Physician Payments Sunshine Act was placed into law in 2010 in an effort to create transparency between physicians and industry. Along with many other specialties, orthopaedic surgeons have long worked intimately with medical industry companies. This study aimed to evaluate trends in industry payments to general orthopaedic surgeons from 2014 to 2019. Methods: A retrospective review of the Center of Medicare and Medicaid Services' Open Payments Database was done to identify all industry payments to all general orthopaedic surgeons (ie, not subspecialty affiliated) from 2014 to 2019. The researchers analyzed total payments and subtype payments for yearly trends, and a regional analysis was done. The primary outcome was the overall trend in total median payments, which was assessed through the Jonckheere-Terpstra test. Descriptive statistics include medians with interquartile ranges. P < 0.05 was considered statistically significant. Results: Between 2014 and 2019, a total of 1,330,543 payments totaling $1.79 billion dollars was paid to 108,041 general orthopaedic surgeons. During this time, the number of surgeons receiving payments increased with a significant uptrend in median payments per surgeon (P < 0.001; Table 1). The top 25% percentile of general orthopaedic surgeons received >95% of payments, whereas the bottom 25% received <0.1%. The general payment types all saw significant increases (P < 0.001) between 2014 and 2019, with the exception of “Ownership or Investment Interests” (P = 0.657) and “Royalty or License” (P = 0.517). Significant regional uptrends in median industry payments were also seen in the Midwest, Northeast, South, and West (P < 0.001). Four of the top five orthopaedic industry companies made payment increases between 2014 and 2019. Conclusion: Industry payments to general orthopaedic surgeons between 2014 and 2019 have increased with a considerable disparity in payments among the top-paid orthopaedic surgeons.

13 August 2024 in Injury
Verified
Journal Article
Closed access
NDNiloofar Dehghan
Niloofar Dehghan
NFNicholas Frane
Nicholas Frane
AVArjun Vohra
Arjun Vohra
RORobert O'COnnor
Robert O'COnnor
SDSorka Deeyor
Sorka Deeyor
MMMichael McKee
Michael McKee